# Subcutaneous infliximab in inflammatory bowel disease: bridging the gap between theory and practice

## TL;DR

This review discusses the benefits and evidence for using subcutaneous infliximab in inflammatory bowel disease, highlighting its potential to improve patient care.

## Contribution

The paper provides a comprehensive review of clinical evidence for subcutaneous infliximab in IBD, focusing on its practical implications.

## Key findings

- Subcutaneous infliximab leads to higher serum levels and fewer antibodies compared to intravenous administration.
- Switching to subcutaneous infliximab is well accepted and associated with low relapse risk in real-world settings.
- At-home administration of subcutaneous infliximab improves patient satisfaction and reduces healthcare burdens.

## Abstract

At the end of the past century, infliximab (IFX), the first-in-class biological therapy approved in inflammatory bowel disease (IBD), dramatically modified the therapeutic armamentarium. The recent development of subcutaneous (SC) formulations of IFX offers a promising alternative, with the potential to improve patient convenience, adherence, and overall outcomes. This review explores the clinical evidence supporting the initiation of SC IFX and the transition from intravenous (IV) to SC IFX.

Comprehensive review using MEDLINE (source PUBMED).

Comparative studies have shown that SC IFX is associated with higher IFX serum concentration levels than IV, fewer neutralizing antibodies and similar levels of remission. Real-world studies have confirmed that switching from IV to SC IFX 120 mg is well accepted with a low risk of relapse. The ease of at-home administration has been associated with improved patient satisfaction and reduced healthcare burdens. The adoption of SC IFX could profoundly change the therapeutic landscape, offering a more patient-centered approach to long-term disease control but some questions remain, particularly about the place of IFX in certain populations.

In this article, we reviewed the known and unknown data on SC IFX to provide a comprehensive summary and assist IBD physicians in integrating this knowledge into everyday clinical practice.